Adverse events associated with the use of anticoagulants (e.g. bleeding) ‐ not measured · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain durationScale from: 1 to 7. · people with sickle cell disease
1 finding from 1 review
The requirement for opiate treatment · people with sickle cell disease
1 finding from 1 review
Number of serious complications of SCD ‐ not measured · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of other sickle‐related events ‐ not measured · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalisation (number and duration) ‐ not measured · people with sickle cell disease
1 finding from 1 review
Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events associated with the use of anticoagulants (e.g. bleeding) · people with sickle cell disease
Tinzaparin showed no clear difference in adverse events associated with the use of anticoagulants (e.g.… compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · patients with managing transfusional iron overload in people with sickle cell disease
It is very uncertain whether deferasirox changes mortality compared with deferoxamine (very low certainty).
1 finding from 1 review
End‐organ damage (incidence of diabetes) · patients with managing transfusional iron overload in people with sickle cell disease
It is very uncertain whether deferasirox changes end‐organ damage (incidence of diabetes) compared with deferoxamine (very low certainty).
1 finding from 1 review
LIC · patients with managing transfusional iron overload in people with sickle cell disease
1 finding from 1 review
Ferritin (µg/L) · patients with managing transfusional iron overload in people with sickle cell disease
1 finding from 1 review
AE: Change in creatinine from baseline (µmol/l) · patients with managing transfusional iron overload in people with sickle cell disease
1 finding from 1 review
Overall discontinuation ( · patients with managing transfusional iron overload in people with sickle cell disease
Deferasirox may leads to lower discontinuations compared with deferoxamine (low certainty).
1 finding from 1 review
Satisfaction · patients with managing transfusional iron overload in people with sickle cell disease
Deferasirox probably leads to higher satisfaction compared with deferoxamine (moderate certainty).
1 finding from 1 review
Intervention not reported
Total ITI Success · persons with severe haemophilia A and factor inhibitory antibodies
The intervention showed no clear difference in total ITI Success (moderate certainty).
1 finding from 1 review
Intervention not reported
All bleeding events · persons with severe haemophilia A and factor inhibitory antibodies
The intervention may leads to higher all bleeding events (low certainty).
1 finding from 1 review
Intervention not reported
CVAD infections · persons with severe haemophilia A and factor inhibitory antibodies
The intervention showed no clear difference in CVAD infections (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe allergic reaction · persons with severe haemophilia A and factor inhibitory antibodies
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found